[go: up one dir, main page]

UY38168A - BI-SPECIFIC ANTIBODY THAT JOINS SUBDOMINES IV AND II OF THE EXTRACELLULAR DOMAIN OF HUMAN HER2 - Google Patents

BI-SPECIFIC ANTIBODY THAT JOINS SUBDOMINES IV AND II OF THE EXTRACELLULAR DOMAIN OF HUMAN HER2

Info

Publication number
UY38168A
UY38168A UY38168A UY38168A UY38168A UY 38168 A UY38168 A UY 38168A UY 38168 A UY38168 A UY 38168A UY 38168 A UY38168 A UY 38168A UY 38168 A UY38168 A UY 38168A
Authority
UY
Uruguay
Prior art keywords
extracellular domain
human her2
specific antibody
subdomines
joins
Prior art date
Application number
UY38168A
Other languages
Spanish (es)
Inventor
Aleksandra Aleksandrovna Sozonova
Mariia Aleksandrovna Shchemeleva
Pavel Andreevich Iakovlev
Elena Andreevna Krendeleva
Dmitry Valentinovich Morozov
Alexander Vladimirovich Prokofyev
Nina Grachyaevna Kharatian
Viktoriya Olegovna Shitikova
Arina Vitalevna Anikina
Olga Viktorovna Nazarenko
Anna Valentinovna Evstrateva
Aleksei Vladimirovich Cherkasov
Alexey Konstantinovich Misorin
Iakov Iurevich Ustiugov
Aleksei Aleksandrovich Aleksandrov
Mariia Igorevna Lomovskaia
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY38168A publication Critical patent/UY38168A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y proporciona un anticuerpo bi-específico que se une específicamente al subdominio IV del dominio extracelular (ECD4) del HER2 humano (receptor del factor de crecimiento epidérmico 2) y el subdominio II del dominio extracelular (ECD2) del HER2 humano. La invención se refiere asimismo al ADN que codifica dicho anticuerpo, los correspondientes vectores de expresión y métodos de producción de los mismos, así como a métodos de tratamiento que emplean dicho anticuerpo.The present invention relates to the field of biotechnology and provides a bi-specific antibody that specifically binds to subdomain IV of the extracellular domain (ECD4) of human HER2 (epidermal growth factor receptor 2) and subdomain II of the extracellular domain ( ECD2) of human HER2. The invention also relates to the DNA encoding said antibody, the corresponding expression vectors and methods of production thereof, as well as to treatment methods using said antibody.

UY38168A 2018-03-29 2019-03-29 BI-SPECIFIC ANTIBODY THAT JOINS SUBDOMINES IV AND II OF THE EXTRACELLULAR DOMAIN OF HUMAN HER2 UY38168A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018111298A RU2018111298A (en) 2018-03-29 2018-03-29 A bispecific antibody that specifically binds to the IV and II subdomains of the extracellular domain of human HER2

Publications (1)

Publication Number Publication Date
UY38168A true UY38168A (en) 2019-10-31

Family

ID=68058434

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38168A UY38168A (en) 2018-03-29 2019-03-29 BI-SPECIFIC ANTIBODY THAT JOINS SUBDOMINES IV AND II OF THE EXTRACELLULAR DOMAIN OF HUMAN HER2

Country Status (5)

Country Link
AR (1) AR115311A1 (en)
RU (1) RU2018111298A (en)
TW (1) TW202003038A (en)
UY (1) UY38168A (en)
WO (1) WO2019190359A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119462944B (en) * 2024-12-02 2025-12-09 中国人民解放军军事科学院军事医学研究院 Human EGFR 2 monoclonal antibody and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354717B (en) * 2012-03-16 2018-03-16 Covagen Ag Novel binding molecules with antitumoral activity.
MX376384B (en) * 2013-11-27 2025-03-07 Zymeworks Bc Inc BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETED AT HER2.

Also Published As

Publication number Publication date
RU2018111298A (en) 2019-10-01
TW202003038A (en) 2020-01-16
WO2019190359A1 (en) 2019-10-03
AR115311A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
MX2020006408A (en) Bi-specific antigen binding molecules.
SA519410710B1 (en) Specific antibodies for FLT3 and their uses
CY1122456T1 (en) MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
PH12019502283A1 (en) Anti-lag3 antibodies
AR119295A1 (en) CEA BINDING ANTIGEN-BINDING MOLECULES
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MX2019007795A (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 20H4.9 ANTI-4-1BB.
EA201791554A1 (en) BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2020006715A (en) SPECIFIC ANTIBODIES TO CD3-DELTA/EPSILON HETERODIMER.
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
MX389789B (en) CHIMERICAL ENVELOPEMENT RECEPTOR MOLECULES.
CL2017001090A1 (en) Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods
MX2018010733A (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore.
JO3788B1 (en) Antibody constructs for egfrviii and cd3
JO3671B1 (en) Anti-DLL3 and CD3 antibody constructs
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
MX385853B (en) ANTIBODIES AND ANTI-EGFR ANTIBODY-DRUG CONJUGATES.
MX384418B (en) Bi-specific single-chain antibody construct with enhanced tissue distribution.
MX2018000880A (en) INHIBITORS OF THE RECEIVER OF THE COLONIAS STIMULATING FACTOR 1 (CSF-1R).
MX2018015280A (en) ANTIBODY CONJUGATES AND ANTI-EGFR DRUG.
CO2019011458A2 (en) Monoclonal antibody to pd-l1
MX2021007119A (en) Methods of producing heterodimeric antibodies.
MX2022007368A (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH CHIMERIC ANTIGEN RECEPTORS DIRECTED TO GLYPICAN 3.
MX2022009815A (en) BISPECIFIC BINDING MOLECULES.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240513